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Human papillomavirus (HPV) infection has now been accepted as
the primary cause of cervical neoplasia (Schiffman, 1992; Bosch
et al, 1995; IARC, 1995; Walboomers et al, 1999). Oncogenic
genital HPVs, however, are highly prevalent in many populations
where CIN3 and cervical cancer remain relatively rare (Bauer 
et al, 1991, 1993; Hildesheim et al, 1993; Melkert et al, 1993;
Wheeler et al, 1993) and natural history studies have shown that
most infections are transient and not associated with detectable
cytological abnormality (Evander et al, 1995; Hinchliffe et al,
1995; Ho et al, 1998). The reasons for this variable natural history
are poorly understood but it has been generally assumed that other
causes or co-factors must be important for the development of
neoplasia in HPV-infected individuals. In addition to sexual
activity, case-control studies have identified a number of other
possible factors including high parity, the presence of other chronic
genital infections, cigarette smoking and oral contraceptive use
(Brinton, 1992). These effects may, however, be due at least partly
to the correlation between sexual behaviour and other risk factors,
and the failure in most studies to control adequately for con-
founding by HPV (Layde, 1989; Phillips and Davey Smith, 
1994). 
In an attempt to resolve these problems, and to distinguish
between risk factors for the acquisition of cervical HPV infection
and co-factors for the development of CIN3 among those infected,
we have conducted a three-arm interview-based case-control study
in which the basis for case and control selection was HPV infec-
tion as well as disease status. The study was nested in a large popu-
lation-based cohort undergoing routine cervical screening in the
city of Manchester, where cervical cell samples for HPV analysis
had been collected from all participants at entry (Peto et al, in
preparation). It includes 199 cases of histologically confirmed
CIN3 diagnosed after entry to the cohort in women known to be
HPV-positive, 181 women infected with HPV but without CIN3
and 203 HPV-negative controls. 
MATERIALS AND METHODS 
The cohort 
The recruitment of the Manchester cohort and the methods of data
collection and follow-up are described elsewhere (Peto et al, in
preparation). Briefly, between 1987 and 1993, in collaboration
with over 100 general practitioners and screening clinics in the
Greater Manchester area who used the Christie Hospital cytology
service, we collected 78 062 cervical cell samples from 61 570
women attending for routine screening. The cell samples were
obtained by elution from spatulas used to take Pap smears. There
was no age restriction for participants. All samples were allocated
a unique identifying number (ID) and were stored in buffer 
at –40˚C. Through regular data linkage of the study IDs with the
main laboratory database, the screening records of cohort mem-
bers and the histology results of any cervical biopsies have been
updated. 
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This study was restricted to white women of any age who had
been routinely and satisfactorily screened at least once through
the Christie laboratory prior to entry to the main cohort, and who
had had a smear and concurrent spatula cell sample (termed
‘spatula’) taken on or after 1 July 1988, that were diagnostically
adequate both for cytology and for PCR. These samples were the
‘index’ smear and spatula that defined a woman’s age and HPV
status. Women were excluded if they had had a hysterectomy, a
previous malignancy or previous CIN3, if they suffered from
serious psychiatric illness, or if they were known to have moved
out of the study area since entry to the cohort. Because of the
temporary nature of their residence in the city, students at
Manchester’s several universities and colleges of further educa-
tion were also excluded. The cytological result of the index 
smear was not a criterion for determining either case or control
eligibility. 
Case identification 
Cases were all those women in the cohort, eligible by the above
criteria, who developed histologically diagnosed CIN3 within 3
years of their index smear. 
Control selection 
Two control groups of approximately equal size were identified,
the first consisting of women found, on PCR screening of their
index spatulas, to be HPV-positive, and the second consisting of
HPV-negative women. No control had CIN3 diagnosed at any time
during her follow-up but women with CIN1 or 2 were not
excluded. Potential controls were identified through stratified
random sampling. All the spatulas collected since 1 July 1988
from eligible women in the cohort were stratified by date (1-year
periods: 1 July 1988 to 30 June 1989, etc) and age of the woman at
the time (5-year age groups: < 20, 20–24, 25–29, etc). Within each
age/period stratum spatulas were submitted for HPV testing in
random order. Testing continued until the number of HPV-positive
spatulas identified roughly equalled the number of cases in each
stratum. In instances where a woman had two or more spatulas
independently selected for random testing, the earlier was defined
as her index. Controls approached for interview were the first
HPV-positive and HPV-negative women in their stratum to be
identified by the random HPV testing. 
HPV detection and genotyping 
HPV DNA in the index spatulas of cases and the random potential
controls was assayed at the Institute of Cancer Research using L1
consensus PCR amplification with the MY09/MY11 primer pair as
described in detail elsewhere (Bauer et al, 1992; Manos et al,
1989). Concurrent amplification of a 286 bp human β -globin frag-
ment was used as an internal control, its failure to amplify desig-
nating a sample inadequate. Consensus HPV-product was detected
using a biotinylated generic probe and enhanced chemilumines-
cence (Amersham International). Positive samples were hybrid-
ized with type-specific oligonucleotide probes to determine the
virus genotypes present (types 6/11/42 (mixed), 16, 18, 26, 31, 33,
35, 39, 40, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 73, ME180, PAP88
(HPV66), PAP155, PAP291 and W13B). Samples positive to the
generic probe but negative to all type-specific probes were desig-
nated as positive, but untyped. 
Interviews 
The ID numbers of potentially eligible cases and controls with
adequate HPV results were identified to the Christie Hospital,
where eligibility was checked as far as was possible from routine
records. A senior clinician (RY) then contacted the general practi-
tioner of each woman to obtain approval for an interviewer to
contact the patient and invite her to participate. Between August
1990 and July 1996 interviews were conducted in the women’s
homes by one of two trained interviewers using a structured
questionnaire. Information collected included demographic data,
menstrual, reproductive and gynaecological history, sexual history
and information on smoking habits. Sexual, contraceptive and
reproductive histories were collected on a calendar with a record
for every month of a woman’s life from the age of menarche (or
first intercourse, whichever was earlier) up to the date of index
smear. Inconsistent data were rechecked with study participants by
telephone. The data were then anonymized, coded and entered on
computer. 
Statistical analysis 
All risk factor analyses relate to exposures prior to the index
spatula date. Two separate analyses were performed. The first,
analysing risk factors for the acquisition of HPV infection,
compared HPV-positive controls with HPV-negative controls. The
second, analysing risk factors for the development of CIN3 among
those infected with HPV, compared the CIN3 cases with the HPV-
positive controls. The age stratification of the study design was
maintained in univariate and multivariate conditional logistic
regression analyses (Breslow and Day, 1980) using the STATA for
Windows® program package. Relative risks were estimated as
odds ratios (OR) with approximate 95% confidence intervals. χ 2
values for differences are Mantel–Haenszel corrected. Tests for
linear trend of log odds were performed by scoring categories of
exposure and fitting them as continuous variables. All P values are
two-sided. 
RESULTS 
315 potential cases and 583 potential controls were identified by
the HPV laboratory and determined from the cytology database
and GP records to be eligible. Of these, 232 cases (74%) and 384
controls (181 HPV-positive and 203 HPV-negative, total 66%)
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Table 1 Age distributions of interviewed women by case/control status 
Age HPV+ve CIN3 Cases HPV+ve Controls HPV–veControls 
(n) (%) (n) (%) (n) (%) 
< 20 4 (2.0) 7 (3.8) 5 (2.5) 
20–24 19 (9.6) 19 (10.5) 21 (10.3) 
25–29 52 (26.1) 47 (26.0) 49 (24.1) 
30–34 49 (24.6) 40 (22.1) 47 (23.2) 
35–39 32 (16.1) 29 (16.0) 32 (15.8) 
40–44 23 (11.6) 19 (10.5) 21 (10.3) 
45–49 7 (3.5) 9 (5.0) 12 (5.9) 
50+ 13 (6.5) 11 (6.1) 16 (7.9) 
Total 199 181 203 Manchester case–control study of CIN3 1567
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Table 2 Characteristics of cases and controls: univariate odds ratiosa for HPV infection among controls, and CIN3 among those infected 
HPV+ve Controls vs HPV ve Controls HPV+ve Cases vs HPV+ve Controls 
+ve –ve OR 95% Cl Ca Con OR 95%CI 
Marital status 
Married 83 130 1.00 92 83 1.00
Cohabiting 26 19 2.02b (1.03–3.98) 35 26 1.22 (0.67–2.24) 
Wid/Sep/Div 35 20 2.59c (1.40–4.79) 36 35 0.83 (0.47–1.47) 
Single 37 34 1.61 (0.88–2.94) 36 37 0.95 (0.52–1.71) 
Age left full-time education 
13–15 44 52 1.00 68 44 1.00 
16–18 104 121 0.88 (0.52–1.52) 110 104 0.66 (0.39–1.12) 
19–21 19 18 1.10 (0.50–2.43) 13 19 0.40 (0.17–0.93) 
22+ 14 12 1.24 (0.51–3.02) 8 14 0.34e (0.13–0.90) 
Age at menarche 
≤ 11 24 45 1.00 37 24 1.00 
12 27 28 1.68 (0.81–3.51) 42 27 1.03 (0.51–2.09) 
13 57 56 1.85 (1.00–3.45) 50 57 0.55 (0.27–1.04) 
14 45 43 1.90 (0.99–3.62) 39 45 0.53 (0.27–1.04) 
15+ 28 31 1.61 (0.79–3.28) 31 28 0.71 (0.34–1.47) 
Number of full-term pregnancies 
0 71 64 1.00 63 71 1.00
1 33 37 0.79 (0.44–1.42) 46 33 1.57 (0.88–2.77) 
2 51 68 0.68 (0.40–1.17) 49 51 1.13 (0.64–1.99) 
3+ 26 34 0.69 (0.35–1.38) 41 26 1.90 (0.94–3.85) 
Age at first birth 
15–19 28 35 1.00 41 28 1.00 
20+ 82 104 0.93 (0.51–1.71) 95 82 0.74 (0.41–1.33) 
Ever had a spontaneous abortion 
No 152 185 1.00 169 152 1.00 
Yes 29 18 2.24b (1.17–4.30) 30 29 0.95 (0.54–1.68) 
Ever had an induced abortion 
No 154 189 1.00 176 154 1.00 
Yes 27 14 2.35b (1.18–4.67) 23 27 0.75 (0.41–1.36) 
Age at first intercourse 
≤ 16 52 58 1.00 87 52 1.00 
17–20 104 113 1.08 (0.67–1.74) 98 104 0.51 (0.32–0.80) 
21+ 25 32 0.90 (0.45–1.84) 14 25 0.25g (0.11–0.57) 
Total number of sexual partners 
1 39 83 1.00 39 39 1.00 
2–5 100 93 2.28 (1.40–3.70) 121 100 1.24 (0.72–2.12) 
6+ 40 25 3.52f (1.84–6.76) 39 40 0.96 (0.50–1.84) 
Number of regular partners 
1 47 93 1.00 46 47 1.00 
2 50 57 1.79 (1.06–3.04) 82 50 1.66 (0.96–2.88) 
3 49 26 3.82 (2.07–7.05) 39 49 0.82 (0.45–1.51) 
4+ 34 26 2.65h (1.41–4.99) 32 34 0.91 (0.48–1.75) 
Years since start of latest regular relationship 
<2 50 21 1.00 24 50 1.00 
2–5 56 37 0.72 (0.37–1.39) 48 56 1.65 (0.87–3.13) 
6+ 74 144 0.19h (0.10–0.35) 127 74 4.06h (2.21–7.44) 
Ever had a sexually transmitted disease 
No 100 108 1.00 102 100 1.00
Yes 81 95 0.91 (0.61–1.37) 97 81 1.16 (0.77–1.74) 
Ever had a partner with genital warts 
No 170 199 1.00 187 170 1.00 
Yes 11 4 3.01 (0.95–9.60) 12 11 1.04 (0.44–2.42) 
Months using barrier contraception 
0 101 95 1.00 110 101 1.00 
1–12 28 26 1.00 (0.55–1.84) 29 28 0.91 (0.50–1.64) 
13–48 24 38 0.59 (0.33–1.06) 32 24 1.20 (0.66–2.19) 
49+ 28 44 0.64 (0.36–1.14) 28 28 0.93 (0.51–1.70) 
Oral contraceptive use 
Never 35 38 1.00 32 35 1.00 
Ex-user 96 116 0.78 (0.43–1.43) 108 96 1.15 (0.63–2.10) 
Current user 50 49 0.95 (0.48–1.89) 59  50 1.28 (0.66–2.50) 
Ever smoked 
No 92 98 1.00 65 92 1.00 
Yes 89 105 0.90 (0.60–1.35) 134 89 2.20d (1.44–3.35) 
aStratified by 5-year age group; bP < 0.05; cP < 0.005; dP < 0.0005; eP for trend < 0.01; fP for trend < 0.001; gP for trend < 0.0005; hP for trend < 0.0001were successfully interviewed. Among the interviewed cases there
were 33 (14%) whose index spatula tested HPV-negative with the
L1 consensus primer system in spite of multiple attempts at ampli-
fication under different conditions. These women did not differ
from the HPV-positive cases with regard to age, cytology results,
social class, sexual, obstetric or contraceptive history. They were
50% more likely than HPV-positive cases to have smoked but this
difference was not significant (χ 2
(1df) = 0.63, P = 0.43). PCR using
different primers has not yet been attempted with these samples
and it is not clear whether they represent truly HPV-unrelated
CIN3 or if they are false-negatives. Because of this uncertainty
these cases have been excluded from the current analyses. The
data presented thus relate to 199 HPV-positive cases of CIN3, 181
HPV-positive controls and 203 HPV-negative controls. 
The refusal rate was low and similar in cases and controls (15%
and 13% respectively) and was unrelated to age. The main reason
for failure to interview was inability to trace the woman (18%
overall). Untraced women were those whose medical records and
health authority registers recorded them as being still resident, but
whom the interviewers found not to be at their registered address.
Among both cases and controls untraced women were signific-
antly younger than those interviewed, reflecting the high mobility
of a fit young urban population; χ 2
(1df) for the difference between
women under 30 and over 30 years was 8.67 (P < 0.005) for the
cases and 15.13 (P < 0.0005) for controls. Significantly more
controls (20%) than cases (11%) remained untraced at the end of
the study (χ 2
(1df) for the difference = 12.81, P < 0.0005), probably
because the cases were under continuing medical surveillance and
hence their records were more accurate. Four controls (2 HPV
infected, 2 uninfected) who did not answer all the sexual questions
and one HPV negative control who reported no regular partners
were excluded from multivariate analyses involving these
variables (see Table 5).
Table 1 shows the age distributions of cases and controls. These
have been balanced by the stratified sampling process and reflect
the age distribution of participating CIN3 cases. All the cases were
diagnosed as the direct result of an abnormal smear, and as this
study was conducted early in the history of the cohort it was the
index smear that was abnormal in each case, 91 (46%) showing
severe dyskaryosis and 108 (54%) showing lower grades of 
abnormality from atypia to moderate dyskaryosis. Among the 
HPV-positive controls 22 (12%) had an index smear showing a
transient mild abnormality that resolved within a year. A further 22
had persistent dyskaryosis and of these 11 had mild or moderate
dysplasia found at biopsy. Cytological abnormality was rare in
uninfected women, seven (3.5%) having transient dyskaryosis and
one having reportedly persistent severe dyskaryosis that showed
CIN1 on biopsy. 
Table 2 shows the distributions of cases and controls according
to selected characteristics and risk factors. Odds ratios are strati-
fied by age according to the 5-year strata used for sampling, but
are otherwise unadjusted. In none of the analyses was there any
evidence of heterogeneity of risk according to age. Among the
controls risk of HPV infection was very strongly related to sexual
behaviour. Both a woman’s total lifetime number of sexual part-
ners and her number of regular (longer than 3 months) relation-
ships were highly predictive of risk (P for trend < 0.001).
HPV-infected women were also much more likely than uninfected
controls to have commenced a new regular relationship within the
past year. There was a moderately significant association between
infection and history of miscarriage that was consistent in all
analyses, remaining essentially unchanged after multivariate
regression (see Table 5). No other risk factors for HPV infection
were identified. The associations between marital status, thera-
peutic abortion and HPV infection disappeared after adjustment
for number of partners and recency of the latest relationship. There
was no association in this data set between cervical HPV infection
and history of other sexually transmitted diseases (trichomonas,
genital warts, genital herpes or gonorrhoea), use of barrier
contraception, oral contraceptives (OCs) or smoking. 
In the comparison of HPV-positive CIN3 cases against HPV-
positive controls the only important determinants of disease were
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Table 3 Univariate odds ratiosa for different smoking variables 
HPV+ve Controls vs HPV–ve Controls HPV+ve Cases vs HPV+ve Controls 
+ve –ve OR 95% Cl Ca Con OR 95%Cl 
Ever smoked 
No 92 98 1.00 65 92 1.00 
Yes 89 105 0.90 (0.60–1.35) 134 89 2.20b (1.44–3.35) 
Current daily smoking habit 
(cigarettes/day) 
Never 92 98 1.00 65 92 1.00 
Ex 15 27 0.66 (0.32–1.35) 22 15 2.14 (1.03–4.45) 
1–19 35 45 0.79 (0.46–1.34) 38 35 1.58 (0.88–2.84) 
20+ 39 33 1.23 (0.72–2.11) 74 39 2.71c (1.64–4.50) 
Duration of smoking (years) 
Never 92 98 1.00 65 92 1.00 
1–9 26 25 1.07 (0.54–2.11) 30 26 1.79 (0.89–3.60) 
10–19 43 46 1.02 (0.61–1.72) 63 43 1.97 (1.17–3.32) 
20+ 20 34 0.63 (0.32–1.23) 41 20 3.13d (1.57–6.23) 
Average no. of cigarettes/day 
when smoking 
Never 92 98 1.00 65 92 1.00 
1–10 33 38 0.89 (0.51–1.56) 29 33 1.36 (0.73–2.51) 
11–16 28 38 0.77 (0.44–1.36) 45 28 2.20 (1.24–3.89) 
17+ 28 29 1.10 (0.60–2.00) 60 28 3.06e (1.77–5.31) 
aStratified by 5-year age group; bP < 0.0005; cP for trend < 0.0005 among current smokers; dP for trend < 0.0005; eP for trend < 0.0001 Manchester case–control study of CIN3 1569
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age at first intercourse, long duration of the latest regular sexual
relationship, and smoking. A moderate association with educa-
tional level and parity disappeared after adjustment for these vari-
ables. These findings are in complete contrast to the risk factors for
infection per se. The association between disease and time since
start of the most recent relationship, which is very strong 
and the inverse of that seen in the previous analysis, suggests 
that CIN3 is associated with longstanding persistent HPV infection. 
Table 3 shows the results of further analyses of different
measures of smoking habit. Among HPV-positive women there
was strong evidence for a disease association with highly signific-
ant increasing trends in risk with increasing duration of smoking or
number of cigarettes smoked per day. Modelling the variables
simultaneously showed both dose measures to be important,
although number of cigarettes per day was a stronger predictor of
risk. In none of the analyses was an association found between risk
of HPV infection and smoking. 
Table 4 shows the results of further investigations of oral contra-
ceptive use. Among the controls there was no indication of any
association between OCs and HPV infection. Point estimates for
the highest categories of each measure of use were slightly raised
in CIN3 cases compared with HPV-positive controls, but none
reached conventional levels of significance and there were no
significant trends. 
Table 4 Univariate odds ratiosa for different oral contraceptive variables 
HPV+ve Controls vs HPV–ve Controls HPV+ve Cases vs HPV+ve Controls 
+ve –ve OR 95% Cl Ca Con OR 95%Cl 
Current oral contraceptive use 
Never 35 38 1.00 32 35 1.00 
Ex 96 116 0.78 (0.43–1.43) 108 96 1.15 (0.63–2.10) 
Current 50 49 0.95 (0.48–1.89) 59 50 1.28 (0.66–2.50) 
Total months of use 
Never 35 38 1.00 32 35 1.00 
1–47 38 51 0.66 (0.33–1.33) 42 38 1.19 (0.58–2.43) 
48–95 56 55 0.94 (0.48–1.84) 43 56 0.76   (0.38–1.53) 
96+ 52 59 0.87 (0.45–1.67) 82 52 1.52 (0.80–2.88) 
Months since first started use 
Never 35 38 1.00 32 35 1.00 
1–95 47 40 1.14 (0.48–2.75) 33 47 0.52 (0.21–1.28) 
96–191 56 79 0.60 (0.30–1.21) 76 56 1.23   (0.61–2.48) 
192+ 43 46 0.93 (0.47–1.84) 58 43 1.41 (0.71–2.79) 
Use of any progesterone-only pillb
Never 35 38 1.00 32 35 1.00 
Ever 17 9 1.67 (0.62–4.48) 17 17 1.29 (0.48–3.44) 
aStratified by 5-year age group; bExcludes women who have been on combined oral contraceptives, but never a progesterone-only pill
Table 5 Adjusted odds ratios for HPV infection among controls, and CIN3 among those infected 
HPV+ve Controls vs HPV–ve Controls HPV+ve Cases vs HPV+ve Controls 
+ve –ve OR 95% Cl Ca Co OR 95%Cl 
Age at first intercourse 
≤ 16 52 57 1.00 87 52 1.00 
17–20 102 112 1.08 (0.64–1.83) 98 102 0.57 (0.35–0.94) 
21+ 25 31 1.00 (0.45–2.23) 14 25 0.31b (0.13–0.75) 
Total number of sexual partnersa
1 39 83 1.00 39 39 1.00 
2–5 100 93 2.15 (1.30–3.54) 121 100 0.88   (0.50–1.57) 
6+ 40 24 3.89c (1.99–7.62) 39 40 0.64 (0.32–1.28) 
Years since start of latest regular 
relationship 
<2 50 21 1.00 24 50 1.00 
2–5 56 36 0.77 (0.39–1.53) 48 56 1.72 (0.88–3.35) 
6+ 73 143 0.24c (0.12–0.47) 127 73   4.94c (2.51–9.71) 
Current daily smoking habit 
Never 91 96 1.00 65 91 1.00 
Ex 14 26 0.69 (0.31–1.53) 22 14 1.69 (0.76–3.75) 
1–19 35 45 0.79 (0.44–1.41) 38 35 1.48 (0.79–2.76) 
20+ 39 33 0.94 (0.52–1.70) 74 39 2.57d (1.49–4.45) 
Ever had a spontaneous abortion 
No 150 182 1.00 169 150 1.00 
Yes 29 18 2.59e (1.28–5.21) 30 29 0.84 (0.45–1.56) 
Odds ratios are stratified by age and also adjusted for the other variables in the table, except: a number of partners is not adjusted for
years since start of latest regular relationship (see text). bP for trend < 0.005; cP for trend < 0.0005; dP for trend (in current smokers) 
< 0.001; eP < 0.01 1570 JM Deacon et al 
British Journal of Cancer (2000) 83(11), 1565–1572 © 2000 Cancer Research Campaign
Table 5 shows adjusted odds ratios for the acquisition of HPV
infection and for the development of CIN3 among those infected,
for all variables significantly associated with either outcome in a
multivariate model. The estimates are mutually adjusted, except
that number of partners is not adjusted for time since the beginning
of the latest sexual relationship. This is because in this data set,
given monogamy, close age stratification and age at first inter-
course, the date of the start of the (single) relationship is closely
predictable. The results are little different from those in Table 2
and still show a striking division between factors related to HPV
infection and those predictive of CIN3 in infected women. 
The risk of CIN3 by HPV genotype among infected women is
shown in Table 6. HPV16, by far the most prevalent single virus
type, has been analysed separately. Other viruses have been have
been grouped according to their phylogeny based on nucleotide
and amino acid sequence alignments of E6 sequences as published
by the Human Papillomavirus Database at Los Alamos National
Laboratory (http//hpv-web.lanl.gov) (van Ranst et al, 1993). The
risk of CIN3 was far greater with HPV16 infection than with any
other type, including related genotypes. 
DISCUSSION 
Our most remarkable finding is the striking difference between the
sexual risk factors that predict HPV infection and those that
predict CIN3 among infected women. A woman’s likelihood of
having a detectable HPV infection depends only on her number of
sexual partners and how recently she has acquired a new partner.
The number of partners presumably determines the probability
that she has ever been infected. Most relationships would have
ended many years earlier, and the fact that they still predict her risk
of a usually transient infection suggests that many such episodes
are recurrences of latent long-standing infection. In contrast, HPV
acquired from a new partner is likely to be an initial infection
rather than a recurrence. The main risk factor for CIN3 among
infected women is age at first intercourse, presumably because
duration of exposure is the main risk factor for neoplastic progres-
sion. The fact that number of partners does not increase the CIN3
risk suggests that once a woman has been infected the risk is not
increased by reinfection. The CIN3 risk in infected women who
have not had a recent new partner is presumably high because
diagnosis of CIN3 is often preceded by a period of persistent HPV
detectability which may well be an effect of subclinical neoplastic
progression rather than its cause. This risk factor raises a novel
epidemiological difficulty. We observed a marked protective effect
for HPV infection (OR 0.24) but an increased risk for CIN3 among
those infected (OR 4.94) in women who had not acquired a new
partner in the last 6 years. The corresponding OR for CIN3 using
the HPV-negative controls would be the product of these estim-
ates, which is close to unity. These highly significant opposite
effects are informative in relation to the natural history of HPV
infection and neoplasia, but they illustrate a potentially serious
error in the analysis of such data. If we had chosen random
controls irrespective of their HPV status, most of whom would 
be HPV-negative, an unadjusted analysis would have given the
correct result that recent sexual behaviour has little effect on 
the CIN3 risk; but the same analysis stratified by HPV status
would be dominated by the comparison of CIN3 cases against
HPV-positive controls and would indicate that a woman’s risk of
developing CIN3 decreases abruptly when she begins a new rela-
tionship. This curious statistical artefact arises because most HPV
infections are transient (Hinchliffe et al, 1995) but those preceding
CIN3 diagnosis are persistent (Remmink et al, 1995). A transient
infection acquired from a new partner is usually harmless, at least
in the short term, but the minority of women in long-standing rela-
tionships who are still infected have persistent disease, and are
thus at high risk of developing CIN3. 
Over 99% of the women we interviewed were willing, in confid-
ence, to discuss their sexual history. This, together with the very
low and comparable refusal rate among both cases and controls
leads us to anticipate minimal information bias in the study. A
potential bias, however, is the differential loss of mobile first choice
controls (movers): significantly more HPV-positive controls (27%)
than HPV-negative controls (12%) or CIN3 cases (11%) had moved
and were still untraced at the end of the study. It appears likely that
women who move frequently and who do not re-register with a new
doctor are less likely to be in a permanent or long-term relationship.
We would anticipate that any bias caused by this selection, there-
fore, would tend to weaken all the duration effects we found and so
our relative risk estimates are probably conservative. 
Our analysis of CIN3 incidence in the whole Manchester cohort
(Peto et al, in preparation) shows that CIN3 can develop quite
rapidly in cytologically normal HPV carriers. Such women have a
risk of CIN3 being detected at the following smear of between 5
and 10%. This observation, together with the findings here, indi-
cates that the natural history of CIN3 often includes a long period
of cytologically undetectable HPV infection. 
The significant association between HPV infection and induced
abortion shown in Table 2 disappeared after adjustment for the
variables shown in Table 5, which reduced this OR from 2.35
(P<0.05) to 1.38 (not significant). Similar findings were previously
reported by Karlsson et al. (1995). For spontaneous abortion,
however, the same adjustment increased the OR from 2.24
(P<0.05) to 2.59 (P<0.01). This association between current HPV
infection and previous spontaneous abortion supports the inference
that many prevalent HPV infections are persistent or recurrent
rather than newly acquired. 
Our results show no clear association of oral contraceptive use
with either HPV infection or disease. This is in contrast to a recent
study (Ylitalo et al, 1999) where current use was associated with a
highly significant four-fold increase in risk of CIN3. From Table 4
it can be seen that HPV-infected women who used the pill for 8
years or more, and those whose first use was more than 8 years
earlier, were at marginally increased although not significant risk
of CIN3. We have therefore analysed duration of use more than 8
years before diagnosis. The relative risk was 1.67 (1.03–2.72) in
ever users, but there was no significant trend with duration of use.
Table 6 Risk of CIN3a by HPV genotype among infected women 
HPV+ve Cases vs HPV+ve Controls 
Ca Con OR 95% Cl 
HPV Type 
16 132 55 1.00 
16 Relatedb 37 33 0.48 (0.27–0.86) 
18 & Relatedc 20 31 0.27 (0.14–0.52) 
Otherd 10 62 0.06 (0.03–0.13) 
aOdds ratios stratified by 5-year age group; b31, 33, 35, 52, 58; c18, 39, 45,
59; dall others, including generic probe-positive but type unidentified. When
multiple HPV types were detected women have been categorized by their
highest risk virus according to the ranking in the table Manchester case–control study of CIN3 1571
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This risk was reduced to 1.47 (0.89–2.43) when duration of latest
relationship, which is correlated with long-term pill use, was
included in the model, and further reduced to 1.24 (0.72–2.15)
when adjusted for the other variables listed in Table 5. 
The evidence that smoking increases the risk of CIN3 and
cervical cancer, which has been accumulating over the last 25
years, has recently been reviewed by Szarewski and Cuzick
(1998). They concluded that the increased risk seen in most studies
was reduced but not eliminated by adjustment for age at first inter-
course and number of sexual partners, the residual risk remaining
at or above two-fold in current smokers and showing a dose–
response in many studies. The causal basis of the link, however, is
still controversial because of the marked correlation between
smoking and early sexual behaviour. In our study, for example, the
proportion of controls whose age at first sexual intercourse was 16
or less was 38% among women who had ever smoked and 19%
among never smokers. The prevalence of HPV infection was also
increased among smokers in several studies, although the associa-
tion was reduced by adjustment for sexual variables (Ley et al,
1991; Bauer et al, 1993; Olsen et al, 1998). Szarewski and Cuzick
(1998) noted that adjustment for HPV infection further reduced the
effect of smoking on cervical neoplasia in some studies, raising
further doubts about the causal role of smoking (Morrison et al,
1991; Olsen et al, 1998). The independence of smoking and HPV
infection in this study and the consistent and highly significant
dose-response for CIN3 compared with HPV-infected controls
provide strong evidence that smoking acts synergistically with
HPV to cause cervical neoplasia. 
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APPENDIX 
The Manchester UK cohort: clinical collaborators 
GP Practices: 
Drs D Bodey, S Hollingshead and T Rashid, Wilmslow Road, Fallowfield; 
Drs H Burgess, S Goodman and HC Sutherland, Mauldeth Road, Fallowfield; 
Drs K Checkland, M Jones and K Wells, Church Street, Marple, Stockport; 
Dr DN Riley, Robins Lane Medical Centre, Bramhall; 
Drs E Tierney, JCV Gillighan, JF Downie and AP Morris, Whitworth Medical Centre, Rochdale; 
Partners of the Northenden Group Practice, Palatine Road, Withington; 
Partners of the Robert Darbyshire Practice, Rusholme Health Centre 
Family planning clinics: 
Adswood Clinic, Stockport; Ancoats Hospital; Brinnington Clinic, Stockport; Cheadle Health Clinic, Stockport; Corporation Road Clinic,
Eccles; Grasmere Street Health Centre, Leigh; Hazel Grove Clinic, Stockport; Heaton Norris Clinic, Stockport; Higher Broughton Health
Centre, Salford; Hope Hospital, Salford; Lanceburn Health Centre, Salford; Langworthy Clinic, Salford; Little Hulton Clinic, Worsley;
Liverpool Road Clinic, Hindley; Longsight Health Centre; Lower Broughton Clinic, Salford; Maple Clinic, Stockport; North Reddish
Clinic, Stockport; Northern Hospital, Cheetham; Offerton Clinic Stockport; Offerton Green Clinic, Stockport; Partington Lane Clinic,
Swinton; Romiley Health Centre, Stockport; Shaw Health Clinic, Stockport; St Mary’s Hospital; Stepping Hill Clinic, Stockport; The
Palatine Centre, Palatine Road, Withington; Woodley Clinic, Stockport 
Screening clinics: 
Abbey Hey Clinic, Gorton; Alexandra Park Health Centre; Ancoats Community Clinic; Assheton Road Clinic, Newton Heath; Atherton
Clinic, Wigan; Baguley Clinic; Beech Hill Health Centre, Wigan; Beswick Health Centre; Bevendon Square Clinic, Salford; Boothtown
Clinic; Bramhall Clinic, Stockport; Bredbury Clinic, Stockport; Brookfield Clinics, Stockport; Brunswick Clinic; Burley House Clinic,
Stockport; Central Drive Clinic, Crumpsall; Charlestown Health Centre, Blackley; Child Health Centre, Benchill; Clayton Health Centre;
College Road Clinic, Leigh; Corporation Road Clinic, Eccles; Crumpsall Clinic; Derby Road Clinic, Golborne; Derbyshire House Clinic;
Gorton Combined Clinic, West Gorton; Grasmere Street Health Centre, Leigh; Haig Road Clinic, Aspull; Harpurhey Health Centre; Hazel
Grove Clinic, Stockport; Heaton Norris Clinic, Stockport; Hulme Clinic; Irlam Health Centre; Levenshulme Health Centre; Little Hulton
Clinic, Worsley; Liverpool Road Health Centre, Hindley; Liverpool Street Clinic, Salford; Longshoot Lane Health Centre, Scholes; Lower
Broughton Clinic, Salford; Monton Road Clinic, Eccles; Moss Side Health Centre; Newton Heath Health Centre; Nicholas Road Health
Centre, Chorlton; North Reddish Clinic, Stockport; Offerton Clinic, Stockport; Ordsall Health Centre, Salford; Orrell Road Clinic, Wigan;
Partington Lane Clinic, Swinton; Pemberton Clinic, Wigan; Plant Hill Clinic, Blackley; Platt Bridge Clinic, Wigan; Poplar Street Clinic,
Tyldesley; Queens Road Clinic, Ashton-in-Makerfield; Romiley Clinic, Stockport; Smedley Street Clinic, Crumpsall; Standish Clinic,
Wigan; Varley Street Clinic, Miles Platting; Walkden Clinic; Walmer Street Clinic, Rusholme; Wellwoman Clinic, Woodhouse Park;
Wellwoman Clinic, Irlam; Wellwoman Clinic, Stockport; Wilmslow Road Clinic, Didsbury; Woodhouse Park Clinic, Wythenshawe